We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+9.11%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$7.02B
AUM Growth
+$483M
Cap. Flow
+$199M
Cap. Flow %
2.83%
Top 10 Hldgs %
49.95%
Holding
78
New
10
Increased
26
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$122M
2
ZLAB icon
Zai Lab
ZLAB
+$78.9M
3
DGX icon
Quest Diagnostics
DGX
+$69.7M
4
ABT icon
Abbott
ABT
+$58.5M
5
JBIO
Jade Biosciences
JBIO
+$49.3M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$149M
2
AKRO
Akero Therapeutics
AKRO
+$88.2M
3
GMED icon
Globus Medical
GMED
+$82.3M
4
ALKS icon
Alkermes
ALKS
+$65.5M
5
ARVN icon
Arvinas
ARVN
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
51
Replimune Group
REPL
$1.01B
$19.2M 0.27%
2,065,010
– –
XNCR icon
52
Xencor
XNCR
$1.55B
$18.9M 0.27%
2,402,883
– –
VSTM icon
53
Verastem
VSTM
$592M
$17.6M 0.25%
4,251,616
+6,140
+0.1% +$38.5K
DYN icon
54
Dyne Therapeutics
DYN
$4.9B
$16.1M 0.23%
1,690,567
– –
JBIO
55
Jade Biosciences
JBIO
$1.34B
$14.5M 0.21%
+1,449,273
New +$49.3M
CRNX icon
56
Crinetics Pharmaceuticals
CRNX
$8.92B
$13.4M 0.19%
+467,000
New +$14.4M
CGEM icon
57
Cullinan Oncology
CGEM
$1.14B
$12.8M 0.18%
1,705,960
– –
XGN icon
58
Exagen
XGN
$166M
$11.8M 0.17%
1,696,866
+185,000
+12% +$1.12M
RAPT
59
DELISTED
RAPT Therapeutics
RAPT
$11.8M 0.17%
1,470,499
-1
-0% -$8
CRVS icon
60
Corvus Pharmaceuticals
CRVS
$1.17B
$10.7M 0.15%
2,679,479
– –
PCSC
61
DELISTED
Perceptive Capital Solutions
PCSC
$7.89M 0.11%
742,500
– –
CTMX icon
62
CytomX Therapeutics
CTMX
$753M
$7.86M 0.11%
+3,461,500
New +$5.58M
ALUR
63
DELISTED
Allurion Technologies
ALUR
$6.18M 0.09%
2,542,603
+1,492,540
+142% +$3.87M
WVE icon
64
Wave Life Sciences
WVE
$1.2B
$5.85M 0.08%
900,000
– –
CRGX
65
DELISTED
CARGO Therapeutics
CRGX
$5M 0.07%
1,212,562
-2,912,297
-71% -$12.5M
MIST icon
66
Milestone Pharmaceuticals
MIST
$152M
$4.86M 0.07%
2,506,102
– –
OMDA
67
Omada Health Inc
OMDA
$1.41B
$3.66M 0.05%
+200,000
New +$3.46M
KMTS
68
Kestra Medical Technologies
KMTS
$1.55B
$3.32M 0.05%
200,000
– –
CBLL
69
CeriBell Inc
CBLL
$714M
$2.81M 0.04%
150,000
– –
TENX icon
70
Tenax Therapeutics
TENX
$503M
$2.18M 0.03%
378,346
– –
IMUX icon
71
Immunic
IMUX
$195M
$280K ﹤0.01%
+40,211
New +$369K
ADGM
72
Adagio Medical Holdings
ADGM
$15.2M
$272K ﹤0.01%
209,361
– –
RCKTW icon
73
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$10.1K ﹤0.01%
350,000
– –
ARVN icon
74
Arvinas
ARVN
$572M
– –
-3,334,308
Closed -$23.4M
BEAM icon
75
Beam Therapeutics
BEAM
$2.84B
– –
-438,659
Closed -$8.57M
1 2
3
4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q2 2025 Portfolio in Review

As of Q2 2025, RTW Investments held 78 positions worth $7.02B, up 7.4% from $6.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments's Q2 2025 filing shows 10 new, 26 increased, 8 reduced and 5 closed positions. Its largest new stake was Neurocrine Biosciences: 1,062,072 shares worth $133M. The largest sale was Axsome Therapeutics, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q2 2025 buy was Neurocrine Biosciences: 1,062,072 shares worth $133M.
  • RTW Investments added most to Zai Lab in Q2 2025, an estimated $78.9M increase.
  • RTW Investments's biggest Q2 2025 reduction was Axsome Therapeutics, cutting an estimated $149M.
  • RTW Investments fully exited Globus Medical in Q2 2025, selling an estimated $82.3M.
  • RTW Investments's ten largest holdings make up 50% of its $7.02B portfolio in Q2 2025.
  • RTW Investments opened 10 new positions and closed 5 in Q2 2025.
  • RTW Investments's portfolio value rose 7.4% quarter-over-quarter to $7.02B.

Based on RTW Investments's 13F filing for Q2 2025, filed 14 Aug 2025.